Rtw Investments Adds $13M in Avalo Therapeutics, Inc. ($AVTX)

RTW Investments recently took a new stake in Avalo Therapeutics, Inc. (NasdaqCM: AVTX), acquiring 856,962 shares. This position, valued at roughly $11.7 million, was disclosed in the firm's latest 13F filing with the SEC. The move marks RTW's initial investment in the biotechnology company.

What Changed in RTW Investments' Avalo Therapeutics Position

RTW Investments' new position in Avalo Therapeutics involved acquiring 856,962 shares, as noted in their latest filing. This acquisition, valued at approximately $11.7 million, represents a fresh stake in the company, as the fund previously held no shares.

Other Institutional Activity in Avalo Therapeutics

Several other institutional investors have also adjusted their positions in Avalo Therapeutics. FMR LLC significantly increased its holdings by 2,659,181 shares, bringing its total to 2,879,481 shares, valued at about $42.99 million. T. Rowe Price Investment Management, Inc. established a new position with 2,162,684 shares worth approximately $32.29 million. Caligan Partners LP added 753,490 shares to its holdings, ending with 1,635,023 shares valued at $24.41 million. Meanwhile, BVF Inc/IL grew its stake by 277,588 shares, totaling 1,632,845 shares valued at $24.38 million.

Avalo Therapeutics Stock Snapshot

Shares of Avalo Therapeutics, Inc. are trading near $13.68 on the Nasdaq. The company has a market capitalization of about $775.9 million. Although it is not currently profitable, it has a forward P/E ratio of -5.27. The stock's 52-week range is between $4.46 and $24.27, with a 50-day moving average of $15.55 and a 200-day moving average of $15.45. Avalo's beta is 0.819, indicating relatively low volatility compared to the market.

Recent Earnings

Avalo Therapeutics reported revenue of $59,000, with no significant growth. The company is not currently profitable, with a negative return on equity of -88.76%. The next earnings report is expected on May 13, 2026.

Insider Buying and Selling at Avalo Therapeutics, Inc.

Recent insider activity includes sales by several executives on June 10, 2026. Jennifer Riley, Chief Strategy Officer, sold 588 shares at $13.10 each. Christopher Ryan Sullivan, the CFO, sold 138 shares at the same price. Paul Varki, Chief Legal Officer, and Mittie Doyle, Chief Medical Officer, sold 1,081 and 1,084 shares, respectively, at $13.10. On June 2, 2026, insiders Michael Thomas Heffernan and Aaron Kantoff each purchased 29,500 and 20,100 shares, respectively, though the transaction price was not specified.

Analysts Set New Price Targets

On June 12, 2026, B of A Securities initiated coverage on Avalo Therapeutics with a 'buy' rating and a $35 price target. Several other firms maintained their 'buy' ratings, including Citizens, Wedbush, and Mizuho, with price targets ranging from $34 to $55. The consensus among analysts is a 'strong buy', with a mean target price of $46.18 based on 11 opinions.

About Avalo Therapeutics

Avalo Therapeutics, Inc. is a biotechnology company based in Wayne, Pennsylvania. Specializing in developing treatments for immune-mediated inflammatory diseases, Avalo's lead product, AVTX-009, is in phase 2 clinical trials. The company, led by CEO Dr. Garry A. Neil, was formerly known as Cerecor Inc. before rebranding in August 2021. Founded in 2011, Avalo employs 33 people.

Bottom Line

RTW Investments' new position in Avalo Therapeutics highlights growing institutional interest in the company. Avalo, a clinical-stage biotech firm, is working on promising treatments for inflammatory diseases. The company's stock has seen significant activity, both from institutional investors and insiders. As always, it's important for investors to remember that 13F filings are backward-looking and may not represent current positions.